Founded in 2018, Neurogene Inc. has concentrated its efforts on developing gene therapies using its patented EXACT platform, which employs microRNA genetic circuits to finely tune transgene expression—an innovation essential for dosage-sensitive neurological diseases like Rett syndrome. The company’s lead candidate NGN-401 is currently in Phase 3 registrational trials with encouraging interim clinical data, supported by an in-house cGMP manufacturing facility that enhances control over quality and timelines. Despite sustained operating losses driven by clinical advancement and R&D investment, Neurogene maintains a strong liquidity position but faces typical early-stage biotech risks including capital demands, regulatory uncertainties, and competitive pressures.